It was reported that induction of host IDO inhibits T-cell functions and generates regulatory T cells through depletion of Trp, leading to immune suppression or tolerance [38].Targeting Trp catabolism in combination with additional therapies improve efficacy of cancer immunotherapy [39]. The gene discussed is IDO1; the disease is cancer.